Nektar Therapeutics Total Assets
Nektar Therapeutics (NKTR) had Total Assets of $1.10 billion as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Assets
us-gaap:Assets · last filed 2026-08-14
- 2026-06-30: Assets $1.10B.
- 2026-03-31: Assets $763.27M.
- 2025-12-31: Assets $280.41M.
- 2025-09-30: Assets $301.35M.
| Period end | Assets | Assets as first filed |
|---|---|---|
| 2026-06-30 | $1.10B 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $763.27M 10-Q · filed 2026-05-08 | |
| 2025-12-31 | $280.41M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $301.35M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $207.53M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $256.24M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $303.85M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $307.97M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $343.33M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $396.01M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $398.03M 10-K · filed 2025-03-14 | |
| 2023-09-30 | $442.24M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $494.28M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $561.74M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $710.60M 10-K · filed 2024-03-05 | |
| 2022-09-30 | $781.01M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $861.99M 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $1.02B 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $1.12B 10-K · filed 2023-02-28 | |
| 2021-09-30 | $1.28B 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $1.37B 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $1.46B 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $1.54B 10-K · filed 2022-03-01 | |
| 2020-09-30 | $1.51B 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $1.59B 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $1.89B 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $1.98B 10-K · filed 2021-02-26 | |
| 2019-09-30 | $2.09B 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $2.10B 10-Q · filed 2019-08-09 | |
| 2019-03-31 | $2.17B 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $2.15B 10-K · filed 2020-02-28 | |
| 2018-09-30 | $2.25B 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $2.31B 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $496.79M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $508.87M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $582.05M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $475.86M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $528.49M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $568.87M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $425.10M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $463.10M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $491.88M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $498.64M 10-K · filed 2017-03-01 | $502.06M 10-K · filed 2016-02-29 |
| 2015-09-30 | $449.25M 10-Q · filed 2015-11-06 | |
| 2015-06-30 | $456.67M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $499.21M 10-Q · filed 2015-05-01 | |
| 2014-12-31 | $441.62M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $476.90M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $478.14M 10-Q · filed 2014-08-01 | |
| 2014-03-31 | $487.01M 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $434.53M 10-K · filed 2015-02-26 | |
| 2013-09-30 | $383.04M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $412.81M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $447.90M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $497.79M 10-K · filed 2014-02-27 | |
| 2012-09-30 | $541.45M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $668.44M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $694.79M 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $606.55M 10-K · filed 2013-03-01 | |
| 2011-09-30 | $648.09M 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $670.85M 10-Q · filed 2011-08-05 | |
| 2011-03-31 | $704.48M 10-Q · filed 2011-04-29 | |
| 2010-12-31 | $521.23M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |